These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34966133)

  • 1. Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications.
    Pirola CJ; Sookoian S
    Curr Opin Lipidol; 2022 Apr; 33(2):95-102. PubMed ID: 34966133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver mitochondrial DNA damage and genetic variability of Cytochrome b - a key component of the respirasome - drive the severity of fatty liver disease.
    Pirola CJ; Garaycoechea M; Flichman D; Castaño GO; Sookoian S
    J Intern Med; 2021 Jan; 289(1):84-96. PubMed ID: 32634278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease.
    Aggeletopoulou I; Kalafateli M; Tsounis EP; Triantos C
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic association study uncovered H3K27 acetylation enhancers and dysregulated genes in high-fat-diet-induced nonalcoholic fatty liver disease in rats.
    Ma J; You D; Chen S; Fang N; Yi X; Wang Y; Lu X; Li X; Zhu M; Xue M; Tang Y; Wei X; Huang J; Zhu Y
    Epigenomics; 2022 Dec; 14(23):1523-1540. PubMed ID: 36851897
    [No Abstract]   [Full Text] [Related]  

  • 5. Epigenetics: An emerging field in the pathogenesis of nonalcoholic fatty liver disease.
    Ashraf NU; Altaf M
    Mutat Res Rev Mutat Res; 2018; 778():1-12. PubMed ID: 30454678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease.
    Li YY
    World J Gastroenterol; 2012 Dec; 18(45):6546-51. PubMed ID: 23236228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic Modifications in the Biology of Nonalcoholic Fatty Liver Disease: The Role of DNA Hydroxymethylation and TET Proteins.
    Pirola CJ; Scian R; Gianotti TF; Dopazo H; Rohr C; Martino JS; Castaño GO; Sookoian S
    Medicine (Baltimore); 2015 Sep; 94(36):e1480. PubMed ID: 26356709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variation in long noncoding RNAs and the risk of nonalcoholic fatty liver disease.
    Sookoian S; Rohr C; Salatino A; Dopazo H; Fernandez Gianotti T; Castaño GO; Pirola CJ
    Oncotarget; 2017 Apr; 8(14):22917-22926. PubMed ID: 28206970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression quantitative trait loci in sheep liver and muscle contribute to variations in meat traits.
    Yuan Z; Sunduimijid B; Xiang R; Behrendt R; Knight MI; Mason BA; Reich CM; Prowse-Wilkins C; Vander Jagt CJ; Chamberlain AJ; MacLeod IM; Li F; Yue X; Daetwyler HD
    Genet Sel Evol; 2021 Jan; 53(1):8. PubMed ID: 33461502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping liver fat female-dependent quantitative trait loci in collaborative cross mice.
    Atamni HJ; Botzman M; Mott R; Gat-Viks I; Iraqi FA
    Mamm Genome; 2016 Dec; 27(11-12):565-573. PubMed ID: 27422773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetics and mitochondrial dysfunction insights into the impact of the progression of non-alcoholic fatty liver disease.
    Guha S; Sesili S; Mir IH; Thirunavukkarasu C
    Cell Biochem Funct; 2023 Jan; 41(1):4-19. PubMed ID: 36330539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide analysis of long noncoding RNA expression profiles in patients with non-alcoholic fatty liver disease.
    Sun C; Liu X; Yi Z; Xiao X; Yang M; Hu G; Liu H; Liao L; Huang F
    IUBMB Life; 2015 Nov; 67(11):847-52. PubMed ID: 26472541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans.
    Liu W; Anstee QM; Wang X; Gawrieh S; Gamazon ER; Athinarayanan S; Liu YL; Darlay R; Cordell HJ; Daly AK; Day CP; Chalasani N
    Aging (Albany NY); 2016 Oct; 9(1):26-40. PubMed ID: 27744419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. System biology analysis reveals the role of voltage-dependent anion channel in mitochondrial dysfunction during non-alcoholic fatty liver disease progression into hepatocellular carcinoma.
    Zhu Y; Zhang C; Xu F; Zhao M; Bergquist J; Yang C; Liu X; Tan Y; Wang X; Li S; Jiang W; Ong Q; Lu L; Mi J; Tian G
    Cancer Sci; 2020 Nov; 111(11):4288-4302. PubMed ID: 32945042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes.
    Jha P; McDevitt MT; Halilbasic E; Williams EG; Quiros PM; Gariani K; Sleiman MB; Gupta R; Ulbrich A; Jochem A; Coon JJ; Trauner M; Pagliarini DJ; Auwerx J
    Cell Syst; 2018 Jun; 6(6):709-721.e6. PubMed ID: 29909275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.
    Speliotes EK; Yerges-Armstrong LM; Wu J; Hernaez R; Kim LJ; Palmer CD; Gudnason V; Eiriksdottir G; Garcia ME; Launer LJ; Nalls MA; Clark JM; Mitchell BD; Shuldiner AR; Butler JL; Tomas M; Hoffmann U; Hwang SJ; Massaro JM; O'Donnell CJ; Sahani DV; Salomaa V; Schadt EE; Schwartz SM; Siscovick DS; ; ; ; Voight BF; Carr JJ; Feitosa MF; Harris TB; Fox CS; Smith AV; Kao WH; Hirschhorn JN; Borecki IB;
    PLoS Genet; 2011 Mar; 7(3):e1001324. PubMed ID: 21423719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropy within gene variants associated with nonalcoholic fatty liver disease and traits of the hematopoietic system.
    Pirola CJ; Salatino A; Sookoian S
    World J Gastroenterol; 2021 Jan; 27(4):305-320. PubMed ID: 33584064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
    Anstee QM; Darlay R; Cockell S; Meroni M; Govaere O; Tiniakos D; Burt AD; Bedossa P; Palmer J; Liu YL; Aithal GP; Allison M; Yki-Järvinen H; Vacca M; Dufour JF; Invernizzi P; Prati D; Ekstedt M; Kechagias S; Francque S; Petta S; Bugianesi E; Clement K; Ratziu V; Schattenberg JM; Valenti L; Day CP; Cordell HJ; Daly AK;
    J Hepatol; 2020 Sep; 73(3):505-515. PubMed ID: 32298765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering the role of epigenetic modifications in fatty liver disease: A systematic review.
    Zhang X; Asllanaj E; Amiri M; Portilla-Fernandez E; Bramer WM; Nano J; Voortman T; Pan Q; Ghanbari M
    Eur J Clin Invest; 2021 May; 51(5):e13479. PubMed ID: 33350463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease.
    Yoo T; Joo SK; Kim HJ; Kim HY; Sim H; Lee J; Kim HH; Jung S; Lee Y; Jamialahmadi O; Romeo S; Jeong WI; Hwang GS; Kang KW; Kim JW; Kim W; Choi M;
    J Hepatol; 2021 Sep; 75(3):514-523. PubMed ID: 33892010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.